Dunzendorfer U, Ohlenschläger G, Zahradnik H P
Onkologie. 1981 Feb;4(1):10-6. doi: 10.1159/000214869.
Prostaglandin F2 alpha can be measured as a stable degradation product, 13,14-dihydro-15-keto-prostaglandin F2 alpha (DHK-PGF2 alpha). Pathological serum levels of this lipid compound have been observed in prostate hyperplasia and treated testicular cancer patients. In renal cancer patients elevated DHK-PGF2 alpha shows a trend to normalize 12 months following nephrectomy in stage T0N0M0. Bladder cancer patients have slightly increased DHK-PGF2 alpha that differ in relation to preinvasive bladder cancer. In contrast serum haptoglobin levels were significantly pathological in patients with kidney and bladder cancer, suggesting involved cancer metabolism. Patients with prostate and testis cancer are without distinct relation to the tumour stage. After specification of haptoglobin types no coincidence to urogenital tumours could be detected. Correlated aberration of PGF2 alpha and haptoglobin displayed different patterns depending on the type of urogenital tumour.
前列腺素F2α可作为一种稳定的降解产物进行测量，即13,14-二氢-15-酮-前列腺素F2α（DHK-PGF2α）。在前列腺增生患者和接受治疗的睾丸癌患者中已观察到这种脂质化合物的病理性血清水平。在T0N0M0期肾癌患者中，肾切除术后12个月，升高的DHK-PGF2α呈现出趋于正常化的趋势。膀胱癌患者的DHK-PGF2α略有升高，这与浸润前膀胱癌有所不同。相比之下，肾癌和膀胱癌患者的血清触珠蛋白水平明显呈病理性，提示癌症代谢参与其中。前列腺癌和睾丸癌患者与肿瘤分期无明显关联。在明确触珠蛋白类型后，未检测到与泌尿生殖系统肿瘤的相关性。根据泌尿生殖系统肿瘤的类型，PGF2α和触珠蛋白的相关异常表现出不同的模式。
